Blebbistatin is a selective non-muscle myosin II (NMII) inhibitor, promotes directional migration of corneal endothelial cells (CECs) and accelerates wound healing, and better preserves cell junctional integrity and barrier function. Blebbistatin blocks cell migration.
性状
Solid
IC50 & Target[1][2]
Non-muscle myosin II (NMII)
体外研究(In Vitro)
The therapeutic potential of targeting NMII to enhance CEC migration is investigated using bovine corneal endothelial cells (BCECs). Blebbistatin, a direct myosin motor inhibitor, promotes migration and directional persistence in CECs through decreasing actin retrograde flow and increasing lamellipodial protrusion persistence to accelerate wound healing 体外研究.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
Blebbistatin (0.05 mL, 20 μM; intracameral injection; daily; for 6 days; New Zealand white rabbits) treatment promotes wound healing in rabbit corneal endothelial scraping model.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
New Zealand white rabbits (16-20 weeks; 3-3.5 kg)
Dosage:
0.05 mL; 20 μM
Administration:
Intracameral injection; daily; for 6 days
Result:
Resulted in significant improvement of corneal clarity and corneal edema resolution, implying the restoration of an intact corneal endothelial monolayer.